Summary
The recent news about Glenmark's COPD drug failing Stage II b clinical trial is infact not to good for the company.
But we need to understand that current revenues & medium term revenues are not affected by this.
The company is sitting on solid fundamentals & is a good back the new reduced valuations!!
The Investment community should take a serious look & keep the cheque books ready!!!
Analysis
Glenmark is a very silent players in India pharma industry compared to its peers.
This is a good opportunity to BUY !!!
One drug not making it, wont have much affect on the company's revenue stream!!!
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
